01 / Research summaries
Study-by-study reading
Short, plain-language summaries identify research questions, study design, reported outcomes, safety observations, and limitations without turning preliminary findings into conclusions.
Independent information offerings / 01—04
Services
Guides, comparisons, and research summaries for evaluating ibogaine addiction research with attention to study quality, safety, and unanswered questions.
What this work is
Context, not a treatment promise.
Gentle Clearing 56 is an independent resource on ibogaine addiction research. Its information services are designed for people seeking careful context, including patients, families, clinicians, and policy-minded professionals. The broader evidence base for ibogaine addiction research is presented as investigational material, not as established treatment guidance.
Our approach to evidence and uncertainty distinguishes what a study can support from what it cannot. That distinction matters because the U.S. Food and Drug Administration notes that products marketed for treatment can require evidence of safety and effectiveness before approval, while ibogaine remains outside that established pathway in the United States.
Information services
Four ways to examine the record.
Move across the rail to see the kinds of context this resource organizes.
02 / Decision frameworks
Questions before claims
Frameworks help readers ask what population was studied, what comparison was used, how outcomes were measured, and what uncertainty remains around ibogaine research.
03 / Comparative context
Adjacent topics, kept distinct
Contextual comparisons examine related questions, including ibogaine treatment costs, without treating cost or availability as evidence of effectiveness or safety.
04 / Glossary and FAQ
Terms made usable
Definitions and focused answers clarify research language, regulatory status, and recurring evidence questions in language that does not assume specialist training.
Safety reading
No evidence summary is complete without risk.
Safety context is not an optional footnote. The FDA consumer alert on ibogaine products describes serious risks, including cardiac events and death. Our guides therefore keep reported adverse events, monitoring limits, exclusions, and unanswered questions in view.
For readers comparing narrower topics, the resource also separates discussion of long-term side effects from the claims made by individual studies. It does not infer safety from limited samples, selected participants, or the absence of reported events.
Evidence is more useful when its boundaries are stated as plainly as its findings.
A working method
The questions behind each guide.
- What was actually studied, and who was included or excluded?
- What outcome is being reported, over what period, and against what comparison?
- Which safety details are described, and which are missing or uncertain?
- What does the evidence say about a specific use, and what would go beyond it?
This approach is especially important when topics overlap. Material on an ibogaine clinic is not interchangeable with evidence about an investigational substance; likewise, discussion of ibogaine and 5-MeO-DMT requires its own evidence and safety framing.
FAQ collection